

CLAIMS

What is claimed is:

1. A method of treating hepatitis pathologies involving TNF in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to monoclonal antibody cA2.
2. A method of treating hepatitis pathologies involving TNF in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF.
3. A method of treating hepatitis pathologies involving TNF in a human comprising administering to the human an effective TNF-inhibiting amount of chimeric anti-TNF antibody cA2.
4. A method for treating hepatitis pathologies involving TNF in a human comprising administering to the human at least one monoclonal antibody cA2, or a TNF binding fragment thereof.
5. A method of treating hepatitis pathologies involving TNF in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises an IgG1 constant region and competitively inhibits binding of TNF to monoclonal antibody cA2.

6. A method of treating hepatitis pathologies involving TNF in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises an IgG1 constant region and binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF.
7. A method of treating hepatitis pathologies involving TNF in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.
8. A method of treating hepatitis pathologies involving TNF in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises an IgG1 human constant region and a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.
9. The method of Claim 7 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:4.
10. The method of Claim 8 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:4.

11. A method of treating inflammation associated with hepatitis pathologies involving TNF in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody has epitopic specificity identical to monoclonal antibody cA2.
- 5
12. A method of treating inflammation associated with hepatitis pathologies involving TNF in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to monoclonal antibody cA2.
- 10
13. A method of treating inflammation associated with hepatitis pathologies involving TNF in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF.
- 15
14. A method of treating inflammation associated with hepatitis pathologies involving TNF in a human comprising administering to the human an effective TNF-inhibiting amount of chimeric anti-TNF antibody cA2.
- 20
15. A method of treating inflammation associated with hepatitis pathologies involving TNF in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody has epitopic specificity identical to monoclonal antibody cA2.